Plant Name: Dracaena cochinchinensis
Taxonomic Information:
Plant ID: NPO12714
Plant Latin Name: Dracaena cochinchinensis
Taxonomy Genus: Dracaena
Taxonomy Family: Asparagaceae
Plant External Links:
NCBI TaxonomyDB:
593754
Plant-of-the-World-Online:
534147-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
Thailand; Vietnam; China; Cambodia; Laos
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PIK3CB; PIK3CA; GFER; NQO2; | |
| CA14; CA12; CA9; | |
| ESR1; | |
| PTGS2; PTGS1; | |
| TP53; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.258E-08 | 1.636E-04 | CYP1A1, CYP1B1, CYP3A4, NQO2, PTGS1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.254E-08 | 1.636E-04 | CYP1A1, CYP1B1, CYP3A4, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.372E-07 | 3.734E-04 | CA12, CA14, CA9 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 1.937E-07 | 4.688E-04 | CA12, CA9, CYP1A1, CYP1B1, CYP3A4, ESR1, NQO2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 4.878E-07 | 8.914E-04 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.322E-07 | 8.914E-04 | CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.181E-06 | 1.354E-03 | CYP1A1, CYP1B1, CYP3A4, GFER, NQO2, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.323E-06 | 1.441E-03 | CYP1A1, CYP3A4, PIK3CA, PIK3CB, PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.463E-06 | 1.517E-03 | CYP1A1, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.944E-06 | 3.579E-03 | CA12, CA14, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.224E-06 | 3.679E-03 | CYP1A1, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.872E-06 | 4.080E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 7.125E-06 | 5.333E-03 | CA12, CA9, CYP1A1, CYP1B1, CYP3A4, PIK3CA, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.305E-06 | 5.333E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0035005; 1-phosphatidylinositol-4-phosphate 3-kinase activity | 1.022E-05 | 6.547E-03 | PIK3CA, PIK3CB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 5.403E-08 | 5.727E-06 | PIK3CA, PIK3CB, PTGS2, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 3.086E-07 | 8.179E-06 | PIK3CA, PIK3CB, PTGS2, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.546E-07 | 8.179E-06 | CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.101E-06 | 2.334E-05 | PIK3CA, PIK3CB, TP53, ESR1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.846E-07 | 8.179E-06 | CA12, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.249E-06 | 8.902E-05 | CYP1A1, CYP1B1, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 7.405E-06 | 8.902E-05 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 5.913E-06 | 8.902E-05 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.525E-06 | 8.902E-05 | PIK3CA, PIK3CB, TP53, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.163E-05 | 9.002E-05 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 9.594E-06 | 8.902E-05 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.008E-05 | 8.902E-05 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.217E-05 | 9.002E-05 | PIK3CA, PIK3CB, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.236E-06 | 8.902E-05 | CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.517E-05 | 9.204E-05 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.274E-05 | 9.002E-05 | PIK3CA, PIK3CB, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.583E-05 | 9.204E-05 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.650E-05 | 9.204E-05 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.993E-05 | 1.586E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.242E-05 | 1.955E-04 | PIK3CA, CYP1B1, PTGS2, TP53 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 3.525E-05 | 1.779E-04 | PIK3CA, PIK3CB, TP53 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.650E-05 | 9.204E-05 | CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 4.116E-05 | 1.955E-04 | PIK3CA, PIK3CB, ESR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 5.638E-05 | 2.490E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.307E-04 | 4.332E-04 | PIK3CA, PIK3CB, PTGS2, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 7.675E-05 | 3.013E-04 | PIK3CA, PIK3CB, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 7.306E-05 | 2.979E-04 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 7.306E-05 | 2.979E-04 | PIK3CA, PIK3CB, TP53 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.155E-04 | 4.080E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 9.919E-05 | 3.755E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.060E-04 | 3.874E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.308E-04 | 4.332E-04 | PIK3CA, PIK3CB, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.652E-04 | 5.306E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 3.404E-04 | 1.018E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 3.554E-04 | 1.018E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 6.952E-04 | 1.837E-03 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.555E-03 | 3.233E-03 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 7.869E-04 | 1.986E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 1.010E-03 | 2.277E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.081E-03 | 3.940E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.104E-04 | 1.837E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 8.949E-04 | 2.156E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.081E-03 | 3.940E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.209E-03 | 3.968E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.162E-03 | 2.514E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.645E-03 | 3.354E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 1.877E-03 | 3.754E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 9.514E-04 | 2.192E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04070 | Phosphatidylinositol signaling system | 2.081E-03 | 3.940E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 2.166E-03 | 3.968E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.209E-03 | 3.968E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.326E-03 | 2.810E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 8.400E-04 | 2.071E-03 | PTGS2, PTGS1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 9.229E-04 | 2.174E-03 | CYP1A1, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.296E-03 | 4.000E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 2.659E-03 | 4.337E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 2.429E-03 | 4.087E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.340E-03 | 4.000E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 5.039E-04 | 1.370E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.322E-04 | 1.018E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 2.340E-03 | 4.000E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.566E-03 | 4.250E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.707E-03 | 4.347E-03 | PTGS2, PTGS1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.999E-03 | 4.674E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 4.428E-04 | 1.235E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.735E-03 | 5.656E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 3.305E-03 | 5.077E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.790E-03 | 5.659E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 3.903E-03 | 5.745E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 4.426E-03 | 6.256E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 2.999E-03 | 4.674E-03 | PIK3CA, PIK3CB |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.307E-03 | 6.170E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 4.132E-03 | 5.999E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 4.855E-03 | 6.684E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.669E-03 | 6.512E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 5.302E-03 | 7.206E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.496E-04 | 1.018E-03 | CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 6.465E-03 | 8.566E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 5.905E-03 | 7.923E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 7.349E-03 | 9.618E-03 | PIK3CA, PIK3CB |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS1; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; PTGS2; PIK3CB; NQO2; TP53; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; TP53; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; TP53; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; TP53; CA9; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
